Polymerase Acidic Subunit I38T Mutant Influenza A(H3N2) Virus Isolated from a Pediatric Patient without Prior Baloxavir Marboxil Treatment in Mie Prefecture (November 2018)

摘要

In Japan，aside from the conventional surveillanceof neuraminidase (NA) inhibitors, a new anti-influenzadrug known as cap-dependent endonuclease inhibitorbaloxavir marboxil (baloxavir,trade name: Xofluza)became available for use since March 2018 during the2017/18 season.A system was established to monitorthis drug under the initiatives of the National Institute ofInfectious Diseases.In cooperation with public healthinstitutes across the nation, a nationwide investigationwas conducted on mutant viruses resistant to baloxavir(1,2).